Evidence map›Paper›PMID 40357402›Full record

Observational studyFrontiers in cellular and infection microbiology2025

Clinical evaluation of personalized

Ruolin Peng, Zhimei Zhang, Chuchu Yang, Zhengyuan Xu, Jiabin Wang, Lei Chen, Sujun Gao, Jian Tao, Meijuan Xi, Xiaofeng Ye and 16 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Third-Line and Later Susceptibility-GuidedJournal of clinical medicine · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ruolin PengDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Zhimei ZhangDepartment of Gastroenterology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, China.
Chuchu YangDepartment of Gastroenterology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, China.
Zhengyuan XuDepartment of Gastroenterology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, Jiangsu, China.
Jiabin WangDepartment of Gastroenterology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Suqian, Jiangsu, China.
Lei ChenDepartment of Gastroenterology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Sujun GaoDepartment of Gastroenterology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China.
Jian TaoDepartment of Gastroenterology, Changshu Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu, China.
Meijuan XiDepartment of Gastroenterology, Changshu Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu, China.
Xiaofeng YeDepartment of Gastroenterology, Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu, China.
Lu ShenDepartment of Gastroenterology, Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu, China.
Qiang ZhanDepartment of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Lijia DinDepartment of Gastroenterology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Jun WangDepartment of Gastroenterology, Jinhu County People's Hospital, Huaian, Jiangsu, China.
Rong OuDepartment of Gastroenterology, Jinhu County People's Hospital, Huaian, Jiangsu, China.
Jianhua CuiDepartment of Gastroenterology, Dongtai People's Hospital, Yancheng, Jiangsu, China.
Lin ChenDepartment of Gastroenterology, Dongtai People's Hospital, Yancheng, Jiangsu, China.
Xiaodan XuDepartment of Gastroenterology, Changshu No.1 People's Hospital, Suzhou, Jiangsu, China.
Gongyu ZhangDepartment of Gastroenterology, Changshu No.1 People's Hospital, Suzhou, Jiangsu, China.
Chunyan XuDepartment of Gastroenterology, The Affiliated Huaian Hospital of Yangzhou University, The Fifth People's Hospital of Huaian, Huaian, Jiangsu, China.
Jing DuDepartment of Gastroenterology, The Affiliated Huaian Hospital of Yangzhou University, The Fifth People's Hospital of Huaian, Huaian, Jiangsu, China.
Guangxia ChenDepartment of Gastroenterology, The First People's Hospital of Xuzhou, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xinxin ZhaoDepartment of Gastroenterology, The First People's Hospital of Xuzhou, Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu, China.
Lamei XuDepartment of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Min XuDepartment of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Zhenyu ZhangDepartment of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Growing antibiotic resistance in Methods: A retrospective, observational study was conducted across 13 hospitals within Jiangsu Province. Fecal samples were analyzed using fluorescence PCR for the Results: A total of 387 participants completed the eradication treatment, with an overall success rate of 91.0% (352/387, 95% CI: 87.6%-93.6%). Among them, 310 individuals received a 14-day course of bismuth quadruple therapy (BQT), achieving an eradication rate of 90.0% (279/310, 95% CI: 86.1%-93.1%). 77 participants were treated with high-dose dual therapy (HDDT) for the same duration, resulting in a slightly higher eradication rate of 94.8% (73/77, 95% CI: 87.2%-98.6%), although this difference was not statistically significant ( Conclusion: PCR detection from fecal samples targeting the resistance genes of

Indexed as

Anti-Bacterial AgentsFecesHelicobacter InfectionsHelicobacter pyloriPolymerase Chain ReactionPrecision MedicineAdultAgedBismuthClarithromycinDNA GyraseDrug Resistance, BacterialDrug Therapy, CombinationFemaleHumansLevofloxacinAnti-Bacterial AgentsBismuthClarithromycinDNA GyraseLevofloxacinRNA, Ribosomal, 23Sdrug resistanceHelicobacter pyloriPCRpersonalized eradicationstool

Identifiers

PMID40357402
PMCPMC12066622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.